{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:03:22Z","timestamp":1787915002764,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Presently, only personal or family history of intracranial aneurysm\/subarachnoid hemorrhage (IA\/SAH) has been established as a risk factor for IA in autosomal dominant polycystic kidney disease (ADPKD). This study aimed to verify the association between kidney function\/volume and IAs in patients with ADPKD. This study included 519 patients with ADPKD. At baseline IA screening, the median age and estimated glomerular filtration rate were 44\u00a0years and 54.5\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, respectively. Family IA\/SAH history was confirmed in 18.1% of the patients, and 54.3% of the patients had hypertension. The IA point prevalence was 12.5%. During clinical follow up of 3104 patient-years, de novo IA was detected in 29 patients (0.93% patient-years). The IA period prevalence was 18.1% (median age, 60\u00a0years). Multivariable logistic regression demonstrated that total kidney volume (TKV)\u2009\u2265\u20091000\u00a0mL (odds ratio [OR]\u2009=\u20092.81), height-adjusted TKV\u2009\u2265\u2009500\u00a0mL (OR\u2009=\u20092.81), Mayo imaging classification Class 1D\u20131E (OR\u2009=\u20092.52), and chronic kidney disease stages 3\u20135 (OR\u2009=\u20092.31) were significantly associated with IA formation. IAs in patients with ADPKD may be associated not only with general risk factors for IAs but also with declining kidney function and increased KV. Kidney disease progression may contribute to effective IA screening and treatment planning in patients with ADPKD.<\/jats:p>","DOI":"10.1038\/s41598-022-22884-9","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T10:03:55Z","timestamp":1666865035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Hiroshi","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Akihisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"22884_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/STROKEAHA.110.578740","volume":"42","author":"HW Xu","year":"2011","unstructured":"Xu, H. W., Yu, S. Q., Mei, C. L. & Li, M. H. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 42, 204\u2013206 (2011).","journal-title":"Stroke"},{"key":"22884_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2215\/CJN.14691218","volume":"14","author":"IM Sanchis","year":"2019","unstructured":"Sanchis, I. M. et al. Presymptomatic screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. CJASN 14, 1151\u20131160 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"22884_CR3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3174\/ajnr.A3456","volume":"34","author":"M Niemczyk","year":"2013","unstructured":"Niemczyk, M. et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. AJNR Am. J. Neuroradiol. 34, 1556\u20131559 (2013).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"22884_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1681\/ASN.V3188","volume":"3","author":"WI Schievink","year":"1992","unstructured":"Schievink, W. I., Torres, V. E., Piepgras, D. G. & Wiebers, D. O. Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 3, 88\u201395 (1992).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22884_CR5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00701-017-3316-8","volume":"159","author":"H Yoshida","year":"2017","unstructured":"Yoshida, H. et al. Relationship between intracranial aneurysms and the severity of autosomal dominant polycystic kidney disease. Acta Neurochir. 159, 2325\u20132330 (2017).","journal-title":"Acta Neurochir."},{"key":"22884_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000513709","volume":"50","author":"CH Lee","year":"2021","unstructured":"Lee, C. H. et al. Clinical factors associated with the risk of intracranial aneurysm rupture in autosomal dominant polycystic kidney disease. Cerebrovasc. Dis. 50, 339\u2013346 (2021).","journal-title":"Cerebrovasc. Dis."},{"key":"22884_CR7","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1056\/NEJMoa070972","volume":"357","author":"MW Vernooij","year":"2007","unstructured":"Vernooij, M. W. et al. Incidental findings on brain MRI in the general population. N. Engl. J. Med. 357, 1821\u20131828 (2007).","journal-title":"N. Engl. J. Med."},{"key":"22884_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1474-4422(11)70109-0","volume":"10","author":"MH Vlak","year":"2011","unstructured":"Vlak, M. H., Algra, A., Brandenburg, R. & Rinkel, G. J. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: A systematic review and meta-analysis. Lancet Neurol. 10, 626\u2013636 (2011).","journal-title":"Lancet Neurol."},{"key":"22884_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(16)30668-7","volume":"389","author":"RL Macdonald","year":"2017","unstructured":"Macdonald, R. L. & Schweizer, T. A. Spontaneous subarachnoid haemorrhage. Lancet 389, 655\u2013666 (2017).","journal-title":"Lancet"},{"key":"22884_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7326\/0003-4819-159-8-201310150-00004","volume":"159","author":"MH Li","year":"2013","unstructured":"Li, M. H. et al. Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: A cross-sectional study. Ann. Intern. Med. 159, 514\u2013521 (2013).","journal-title":"Ann. Intern. Med."},{"key":"22884_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.2215\/CJN.02100219","volume":"14","author":"A Flahault","year":"2019","unstructured":"Flahault, A. & Joly, D. Screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. CJASN 14, 1242\u20131244 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"22884_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman, A. B. et al. Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int. 88, 17\u201327 (2015).","journal-title":"Kidney Int."},{"key":"22884_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrneph.2015.128","volume":"11","author":"RD Perrone","year":"2015","unstructured":"Perrone, R. D., Malek, A. M. & Watnick, T. Vascular complications in autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol. 11, 589\u2013598 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"22884_CR14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s10157-021-02097-6","volume":"25","author":"S Nishio","year":"2021","unstructured":"Nishio, S. et al. A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020. Clin. Exp. Nephrol. 25, 1292\u20131302 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"22884_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10157-015-1219-7","volume":"20","author":"S Horie","year":"2016","unstructured":"Horie, S. et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin. Exp. Nephrol. 20, 493\u2013509 (2016).","journal-title":"Clin. Exp. Nephrol."},{"key":"22884_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ekir.2021.12.012","volume":"7","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Germline mutations for kidney volume in ADPKD. Kidney Int. Rep. 7, 537\u2013546 (2022).","journal-title":"Kidney Int. Rep."},{"key":"22884_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/0092-8674(94)90137-6","volume":"77","author":"The European Polycystic Kidney Disease Consortium","year":"1994","unstructured":"The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 77, 881\u2013894 (1994).","journal-title":"Cell"},{"key":"22884_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki, T. et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272, 1339\u20131342 (1996).","journal-title":"Science"},{"key":"22884_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00946-4","author":"K Dong","year":"2021","unstructured":"Dong, K. et al. Renal plasticity revealed through reversal of polycystic kidney disease in mice. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-021-00946-4 (2021).","journal-title":"Nat. Genet."},{"key":"22884_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010146","author":"H Kataoka","year":"2020","unstructured":"Kataoka, H. et al. Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1\/PKD2 mutations. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm9010146 (2020).","journal-title":"J. Clin. Med."},{"key":"22884_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall, E. et al. Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol. JASN. 24, 1006\u20131013 (2013).","journal-title":"J. Am. Soc. Nephrol. JASN."},{"key":"22884_CR22","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(03)13773-7","volume":"361","author":"S Rossetti","year":"2003","unstructured":"Rossetti, S. et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 361, 2196\u20132201 (2003).","journal-title":"Lancet"},{"key":"22884_CR23","first-page":"e000203","volume":"2","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Mutation type and intracranial aneurysm formation in autosomal dominant polycystic kidney disease. Stroke Vasc. Interv. Neurol. 2, e000203 (2022).","journal-title":"Stroke Vasc. Interv. Neurol."},{"key":"22884_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2013","unstructured":"Mochizuki, T., Tsuchiya, K. & Nitta, K. Autosomal dominant polycystic kidney disease: Recent advances in pathogenesis and potential therapies. Clin. Exp. Nephrol. 17, 317\u2013326 (2013).","journal-title":"Clin. Exp. Nephrol."},{"key":"22884_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12072-021-10176-9","volume":"15","author":"H Kataoka","year":"2021","unstructured":"Kataoka, H. et al. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. Hepatol. Int. 15, 791\u2013803 (2021).","journal-title":"Hepatol. Int."},{"key":"22884_CR26","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s00701-019-04060-7","volume":"161","author":"JY Kim","year":"2019","unstructured":"Kim, J. Y. et al. Intracranial aneurysms in patients receiving kidney transplantation for autosomal dominant polycystic kidney disease. Acta Neurochir. 161, 2389\u20132396 (2019).","journal-title":"Acta Neurochir."},{"key":"22884_CR27","first-page":"1111","volume":"130","author":"M Gradzik","year":"2020","unstructured":"Gradzik, M., Kulesza, A., Go\u0142\u0119biowski, M., P\u0105czek, L. & Niemczyk, M. Intracranial aneurysms in renal transplant recipients with autosomal dominant polycystic kidney disease. Pol. Arch. Med. Wewn. 130, 1111\u20131113 (2020).","journal-title":"Pol. Arch. Med. Wewn."},{"key":"22884_CR28","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1161\/STR.0000000000000070","volume":"46","author":"BG Thompson","year":"2015","unstructured":"Thompson, B. G. et al. Guidelines for the management of patients with unruptured intracranial aneurysms: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 46, 2368\u20132400 (2015).","journal-title":"Stroke"},{"key":"22884_CR29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.kint.2017.08.016","volume":"93","author":"A Flahault","year":"2018","unstructured":"Flahault, A. et al. Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. Kidney Int. 93, 716\u2013726 (2018).","journal-title":"Kidney Int."},{"key":"22884_CR30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2215\/CJN.09731110","volume":"6","author":"MV Irazabal","year":"2011","unstructured":"Irazabal, M. V. et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. CJASN 6, 1274\u20131285 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"22884_CR31","first-page":"506","volume":"38","author":"WE Butler","year":"1996","unstructured":"Butler, W. E., Barker, F. G. 2nd. & Crowell, R. M. Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: A decision analysis. Neurosurgery 38, 506\u2013515 (1996) (discussion 515-506).","journal-title":"Neurosurgery"},{"key":"22884_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"22884_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160\u2013172 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22884_CR34","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1165.1000227","author":"KP Vatcheva","year":"2016","unstructured":"Vatcheva, K. P., Lee, M., McCormick, J. B. & Rahbar, M. H. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology https:\/\/doi.org\/10.4172\/2161-1165.1000227 (2016).","journal-title":"Epidemiology"},{"key":"22884_CR35","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1111\/bph.12856","volume":"172","author":"MJ Curtis","year":"2015","unstructured":"Curtis, M. J. et al. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol. 172, 3461\u20133471 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"22884_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff, E. & McCulloch, C. E. Relaxing the rule of ten events per variable in logistic and Cox regression. Am. J. Epidemiol. 165, 710\u2013718 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"22884_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber, A. B. et al. Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR conjoint analysis good research practices task force. Value Health 19, 300\u2013315 (2016).","journal-title":"Value Health"},{"key":"22884_CR38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2307\/2533006","volume":"51","author":"CM Hurvich","year":"1995","unstructured":"Hurvich, C. M. & Tsai, C. L. Model selection for extended quasi-likelihood models in small samples. Biometrics 51, 1077\u20131084 (1995).","journal-title":"Biometrics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22884-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T10:33:56Z","timestamp":1666866836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22884-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22884-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Toshio Mochizuki received honoraria for lectures from Otsuka Pharmaceutical Co. Toshio Mochizuki, and Hiroshi Kataoka belonged to an endowed department sponsored by Otsuka Pharmaceutical Co., Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., and JMS Co. The remaining authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18056"}}